A proteogenomic pipeline for capture and sequencing and production of pathogen-specific antibodies

A proteogenomic pipeline for capture and sequencing and production of pathogen-specific antibodies - Pathobody2020

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON50850

Enrollment

100

Registered

2021-06-04

Start date

2021-07-01

Completion date

Unknown

Last updated

2024-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Corona COVID-19

Interventions

None listed

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: - Over 18 years of age - Positive PCR in the previous 2 months and/or - Vaccinated against SARS-CoV-2 - Devoid of symptoms associated with an active SARS-CoV-2 infection

Exclusion criteria

Exclusion criteria: - Individuals who cannot or are not willing to consent. - Individuals who are undergoing an immunosuppressive treatment.

Design outcomes

Primary

Measure	Time frame
1. Generate human antibodies with high affinity for SARS-CoV-2, which are neutralizing and cross-reactive against older SARS-Cov viruses, and that target a broad spectrum of epitopes, spread across the viral proteome. Antibodies should preferentially enhance each other's efficacy with regard to virus neutralization. Potent antibodies will be either developed into a product, or offered for licensing to a pharmaceutical party that will continue the path towards the market. 2. Establish a set of IP-protected protocols and procedures as a workflow that rapidly yields monoclonal antibody molecules in response to emerging pathogens.	—

Measure

Time frame

1. Generate human antibodies with high affinity for SARS-CoV-2, which are neutralizing and cross-reactive against older SARS-Cov viruses, and that target a broad spectrum of epitopes, spread across the viral proteome. Antibodies should preferentially enhance each other's efficacy with regard to virus neutralization. Potent antibodies will be either developed into a product, or offered for licensing to a pharmaceutical party that will continue the path towards the market. 2. Establish a set of IP-protected protocols and procedures as a workflow that rapidly yields monoclonal antibody molecules in response to emerging pathogens.

—

Secondary

Measure	Time frame
-	—

Countries

Netherlands

Outcome results